Global Haemophilus Influenzae Infection Market, By Therapy Type (Antibiotics, Glucocorticoids, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Haemophilus Influenzae Infection Market Analysis and Size
The global haemophilus influenzae infection market is expected to witness significant growth during the forecast period. The extensive use of Haemophilus influenzae type b (Hib) conjugate vaccines has nearly eliminated invasive Hib disease wherein the vaccines are used. The most common types of invasive disease that is caused by H. influenzae are pneumonia, bloodstream infection, Cellulitis, Infectious arthritis, meningitis and many others. The Hib vaccine is the ultimate option to protect the child from Hib disease. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global haemophilus influenzae infection market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Haemophilus influenzae infection is an invasive gram-negative bacteria infection that is caused by haemophilus influenzae which affect upper respiratory tract and can spread to others part of the body. The typical sign and symptoms of chills, ear infections, fever, sinusitis and respiratory infections. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Haemophilus Influenzae Infection Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapy Type (Antibiotics, Glucocorticoids, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Lupin (India), Cipla Inc (India), WOCKHARDT (India)
|
|
Market Opportunities
|
|
Global Haemophilus Influenzae Infection Market Dynamics
Drivers
- Increasing Government Initiatives
Several initiatives have been taken by governments and private organizations, such as GAVI and the WHO, to present the haemophilus influenzae type B disease into global immunization programs, which are expected to boost the market. 80% of the GAVI covered countries have successfully provided the vaccine. These initiatives assisted to provide immunization to low income countries at a minimal rate, due to which these vaccines are made accessible worldwide.This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is projected to boost the market growth. This segment is expected to grow the global market as several products are available in capsule form and tablet form and it is a very feasible route of administration.
Opportunities
- Increased Incidence of Haemophilus Influenzae
According to the American Medical Association reports, around 30,000 deaths occur in children between the gae group of 1 to 23 months due to Hib. The death rate caused by Hib is most likely to boost the demand for Hib Vaccine, as the vaccine is the best way to provide protection for the infants and young children from infection. Thus, it creates more opportunities in the future.
- Growing Adoption of Antibiotics and Glucocorticoids
There are two major classes of drugs that are effective in haemophilus influenzae infection treatment called as antibiotics and glucocorticoids. In antibiotics, penicillin are advantageous for the management of mucosal infections that are caused by nonencapsulated H influenzae. Around 25%-50% of isolates produce beta-lactamase that are resistant to this class of drugs. Glucocorticoids are also widely used for the treatment of H influenza. These agents are widely used as adjunctive therapy for the treatment of H influenza meningitis for the anti-inflammatory effects and prevention of sensorineural deafness. Thus, it creates more opportunities in the future.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global haemophilus influenzae infection market over a forecast period.
This global haemophilus influenzae infection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global haemophilus influenzae infection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Haemophilus Influenzae Infection Market
COVID-19 pandemic has caused a unfortunate, consistent decline in childhood vaccination coverage, that includes haemophilus influenzae type b (Hib) vaccine, in many developed countries. This huge decline and shift of Hib vaccination rate because of COVID-19 causes an incremental disease burden irrespective of the possible deterioration of Hib transmission rate through COVID-19 mitigation measures. A huge and quick recovery of vaccination coverage rate can further prevent this possible disease burden and in the post-pandemic era, the market is again rising due to the returning focus on the disease transmission and the production of vaccine.
Global Haemophilus Influenzae Infection Market Scope
The global haemophilus influenzae infection market is segmented on the basis of therapy type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy Type
- Antibiotics
- Glucocorticoids
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Haemophilus Influenzae Infection Market Regional Analysis/Insights
The global haemophilus influenzae infection market is analysed and market size insights and trends are provided by therapy type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global haemophilus influenzae infection market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to the increase’s cases of cardiovascular diseases and rapidly aging population.
North America dominates the market due to the increase prevalence of haemophilus influenzae infection and advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Haemophilus Influenzae Infection Market Share Analysis
The global haemophilus influenzae infection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global haemophilus influenzae infection market
Key players operating in the global haemophilus influenzae infection market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Lupin (India)
- Cipla Inc (India)
- WOCKHARDT (India)
SKU-